Drugs / Allogeneic TCR-enhanced Vδ2 T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07570563 | Jun 2026 → Jun 2029 expected | cancer, hematopoietic and lymphoid system neoplasm | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic TCR-enhanced Vδ2 T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07570563 ↗ |
| Action | Deplete | “thereby significantly boosting tumor cell killing potency” NCT07570563 ↗ |
| Modality | Cell therapy | “The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic.” NCT07570563 ↗ |